Chronic myeloid leukemia (CML) with P190BCR-ABL: Analysis of characteristics, outcomes, and prognostic significance

Blood

Volumn 114, Issue 11, 2009, Pages 2232-2235

  Verma, Dushyant ^a   Kantarjian, Hagop M ^a   Jones, Dan ^a   Luthra, Rajyalakshmi ^a   Borthakur, Gautam ^a   Verstovsek, Srdan ^a   Rios, Mary Beth ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IDARUBICIN; IMATINIB; NILOTINIB; PROTEIN P190; PROTEIN TYROSINE KINASE INHIBITOR; VINCRISTINE; ANTINEOPLASTIC AGENT; CVAD PROTOCOL; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLAST CELL; CANCER PATIENT; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE COURSE; DRUG RESPONSE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; BLAST CELL CRISIS; DISEASE FREE SURVIVAL; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IDARUBICIN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; SURVIVAL RATE; THIAZOLES; VINCRISTINE;

EID: 70349575806     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-204693     Document Type: Article

References (23)

1. Quintás-Cardama A, Cortes A. Molecular biology of BCR-ABL1-positive chronic myeloid leukemia. Blood. 2009;113:1619-1630.
2. Andrikovics H, Nahajevszky S, Szilvási A, et al. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts. Hematol Oncol. 2007;25:143-147. (Pubitemid 47507883)
3. Hur M, Song EY, Kang SH, et al. Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia. Ann Hematol. 2002;81:219-223. (Pubitemid 36067611)
4. Ohsaka A, Shiina S, Kobayashi M, Kudo H, Kawaguchi R. Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCRABL). Intern Med. 2002;41:1183-1187. (Pubitemid 36150023)
5. Ravandi F, Cortes J, Albitar M, et al. Chronic myelogenous leukaemia with p185 (BCR/ABL) expression: characteristics and clinical significance. Br J Haematol. 1999;107:581-586.
6. Verstovsek S, Lin H, Kantarjian H, et al. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer. 2002;94:2416-2425. (Pubitemid 34457123)
7. Pane F, Frigeri F, Sindona M, et al. Neutrophilic chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 1996;88:2410-2414. (Pubitemid 26327488)
8. Leibundgut EO, Jotterand M, Rigamonti V, et al. A novel BCR-ABL transcript e2a2 in a chronic myelogenous leukaemia patient with a duplicated Ph-chromosome and monosomy 7. Br J Haematol. 1999;106:1041-1044. (Pubitemid 29463021)
9. Popovici C, Cailleres S, David M, Lafage-Pochitaloff M, Sainty D, Mozziconacci MJ. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib. Leuk Lymphoma. 2005;46:1375-1377. (Pubitemid 41269307)
10. Melo JV. BCR-ABL gene variants. Baillieres Clin Haematol. 1997;10:203-222.
11. van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood. 1996;87:5213-5217. (Pubitemid 26189863)
12. Selleri L, von Lindern M, Hermans A, Meijer D, Torelli G, Grosveld G. Chronic myeloid leukemia may be associated with several bcr-ab1 transcripts including the acute lymphoid leukemiatype 7 kb transcript. Blood. 1990;75:1146-1153. (Pubitemid 20086823)
13. Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia. 1994;8:208-211. (Pubitemid 2023842)
14. Solves P, Bolufer P, López JA, et al. Chronic myeloid leukemia with expression of ALL-type BCR/ABL transcript: a case-report and review of the literature. Leuk Res. 1999;23:851-854. (Pubitemid 29341476)
15. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446. (Pubitemid 18076421)
16. Luthra R, Medeiros LJ. TaqMan reverse transcriptase-polymerase chain reaction coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Methods Mol Biol. 2006;335:135-145.
17. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937. (Pubitemid 34525471)
18. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
19. Cimino G, Pane F, Elia L, et al. The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. Haematologica. 2006;91:377-380.
20. Gleissner B, Gökbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99:1536-1543. (Pubitemid 34533023)
21. Li S, Ilaria RL Jr, Million RP, Daley GQ, van Etten RA. The P190, P210, P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189:1399-1412. (Pubitemid 29227526)
22. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079-1082. (Pubitemid 20102464)
23. McLaughlin J, Chianese E, Witte ON. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol. 1989;9:1866-1874. (Pubitemid 19117785)